Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Weeks 0-2 Cellular replenishment begins Subtle early shifts are possible including slightly better energy, lighter mornings, and less of a heavy feeling
Clinical research results and study data Semaglutide has one of the most robust clinical trial programs of any peptide in history
its relevance to retatrutide specifically is not yet established A history of pancreatitis or significant gastrointestinal disease Gallbladder disease , including a history of gallstones or cholecystitis Diabetes mellitus , particularly if managed with insulin or sulphonylureas, due to hypoglycaemia risk Cardiovascular disease , including arrhythmias or recent cardiac events Renal or hepatic impairment , which may affect tolerability and increase the risk of dehydration-related complications Pregnancy or breastfeeding no safety data exist for retatrutide in these groups Use of oral medicines where absorption may be affected by delayed gastric emptying , such as levothyroxine or combined oral contraceptives Seek urgent medical attention if you experience severe or persistent nausea or vomiting, persistent abdominal pain (which may indicate pancreatitis or gallbladder disease), signs of an allergic reaction (rash, swelling, difficulty breathing), chest pain, palpitations, or signs of dehydration
H.MayerJ
P (03) 9417 1555 [email protected] www.winnettspecialistgroup.com.au Queens Terrace, 382 Victoria Parade, East Melbourne 3002 Sources: 1* Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes 2* Is coming off semaglutide slowly the key to preventing weight regain
